72547-44-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-METHYL-PIPERAZIN-1-YL)-4-OXO-BUTYRIC ACID is used as a drug intermediate for its potential to contribute to the development of new pharmaceuticals. Its unique structure and properties allow it to be a key component in the synthesis of various medications.
As an Active Pharmaceutical Ingredient:
4-(4-METHYL-PIPERAZIN-1-YL)-4-OXO-BUTYRIC ACID is used as an active pharmaceutical ingredient for its potential therapeutic effects, which are currently under investigation for the treatment of various medical conditions.
In Medicinal Chemistry Research:
4-(4-METHYL-PIPERAZIN-1-YL)-4-OXO-BUTYRIC ACID is used as a subject of research in medicinal chemistry to explore its pharmacological properties and understand its mechanisms of action, which could lead to the discovery of novel treatments and therapies.
For the Development of Drug Formulations:
4-(4-METHYL-PIPERAZIN-1-YL)-4-OXO-BUTYRIC ACID is utilized in the development of drug formulations to enhance the efficacy, safety, and delivery of medications, potentially improving patient outcomes and treatment compliance.

InChI:InChI=1/C9H16N2O3/c1-10-4-6-11(7-5-10)8(12)2-3-9(13)14/h2-7H2,1H3,(H,13,14)

Upstream product

• 109-01-3 1-methyl-piperazine 
• 108-55-4 glutaric anhydride, 
• 108-30-5 succinic acid anhydride 

Relevant academic research and scientific papers

AGONISTS OF THE CHEMOKINE RECEPTOR CXCR3

The present invention relates to agonists of the chemokine receptor CXCR3, methods of their synthesis and uses thereof.

Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3

In this work we report a design, synthesis, and detailed functional characterization of unique strongly biased allosteric agonists of CXCR3 that contain tetrahydroisoquinoline carboxamide cores. Compound 11 (FAUC1036) is the first strongly biased allosteric agonist of CXCR3 that selectively induces weak chemotaxis and leads to receptor internalization and the β-arrestin 2 recruitment with potency comparable to that of the chemokine CXCL11 without any activation of G proteins. A subtle structural change (addition of a methoxy group, 14 (FAUC1104)) led to a contrasting biased allosteric partial agonist that activated solely G proteins, induced chemotaxis, but failed to induce receptor internalization or β-arrestin 2 recruitment. Concomitant structure-activity relationship studies indicated very steep structure-activity relationships, which steer the ligand bias between the β-arrestin 2 and G protein pathway. Overall, the information presented provides a powerful platform for further development and rational design of strongly biased allosteric agonists of CXCR3.

Design, synthesis and biological evaluation of novel pyrenyl derivatives as anticancer agents

Polycyclic aromatic hydrocarbons are widespread in nature with a toxicity range from non-toxic to extremely toxic. A series of pyrenyl derivatives has been synthesized following a four-step strategy where the pyrene nucleus is attached with a basic heterocyclic moiety through a carbon linker. Virtual screening of the physicochemical properties and druggability has been carried out. The cytotoxicity of the compounds (1-8) have been evaluated in vitro against a small panel of human cancer cell lines which includes two liver cancer (HepG2 and Hepa 1-6), two colon cancer (HT-29 and Caco-2) and one each for cervical (HeLa) and breast (MCF-7) cancer cell lines. The IC50 data indicate that compound 6 and 8 are the most effective cytotoxic agents in the present set of pyrenyl derivatives, suggesting that having a 4-carbon linker is more effective than a 5-carbon linker and the presence of amide carbonyl groups in the linker severely reduces the efficacy of the compound. The compounds showed selectivity toward cancer cells at lower doses (51/4M) when compared with the normal hepatocytes. The mechanism of action supports the cell death through apoptosis in a caspase-independent manner without cleavage of poly (ADP-ribose) polymerase (PARP), even though the compounds cause plasma membrane morphological changes. The compounds, whether highly cytotoxic or mildly cytotoxic, localize to the membrane of cells. The compounds with either a piperidine ring (6) or an N-methyl piperazine (8) in the side chain were both capable of circumventing the drug resistance in SKOV3-MDR1-M6/6 ovarian cancer cells overexpressing P-glycoprotein. Qualitative structure-activity relationship has also been studied.

Direct amide bond formation from carboxylic acids and amines using activated alumina balls as a new, convenient, clean, reusable and low cost heterogeneous catalyst

For the first time, we have used activated alumina balls (3-5 mm diameter) for amide synthesis from carboxylic acids (unactivated) and amines (unactivated) under neat reaction conditions that produce no toxic by-products and has the advantages of being low-cost, easily available, heterogeneous, reusable and environmentally benign with no troublesome/hazardous disposal of the catalyst.

COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS

The invention relates to the use of compounds of formula (I): wherein X is -C(O)-, -C(S)-, -C-NOH, or -CH(R7)- wherein R7 is hydrogen, hydroxy, C1-7alkoxy, -OR8 or -NR8R9 (wherein R8

Streptogramin derivatives, their preparation and compositions containing them

Group A streptogramin derivatives of general formula (I) in which:R1 represents a halogen atom or an azido or thiocyanato radical,R2 represents a hydrogen atom or a methyl or ethyl radical,R3 represents a hydrogen atom, or the residue of an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, andthe bond - - -represents a single bond (stereochemistry 27R) or a double bond,as well as its salts when they exist.

Antitumor dibenzofluorene derivatives

Dibenzofluorene derivatives having a formula selected from the group consisting of and salts thereof have antitumor activity. At least one of R1-R13in formula (I) or R1-R12in formula (II) is —R14Z. R14is a substituted or unsubstituted amino or amido group having from 1-12 carbon atoms, and Z is a substituted or unsubstituted heterocyclic group having from 1-12 carbon atoms. The remainder of R1-R13in formula (I) or R1-R12in formula (II) are independently selected from the group consisting of hydrogen, hydroxyl, halogen, nitro, substituted or unsubstituted amino or amido groups having from 1-12 carbon atoms, and alkyl groups having 1-12 carbon atoms.

Polycyclic aromatic compounds as anticancer agents: Structure-activity relationships of chrysene and pyrene derivatives

A large number of diamides and diamines were synthesized using 6-amino chrysene and 1-amino pyrene as starting materials. A structure-activity study with cis-platinum as internal control against animal and human tumor lines was carried out in vitro. This study indicated that the in vitro cytotoxicity toward these lines depends on the functionality present in the molecules. The diamino compounds were found to be more potent than the diamides, and these were equally active irrespective of the end heterocyclic group whereas the activity of the diamides was strongly dependent on the terminal unit. In general, the diamides containing chrysene as the chromophore were more active than those with a pyrene ring. The size of the end heterocyclic ring, along with the nature of the spacer connecting the polycyclic ring to the heterocyclic ring, seemed to affect the biological activity in certain stabilizing agens. This agent also demonstrated the stabilizing agents. This agent also demonstrated the capacity to produce differentiation in leukemia cells lines.

Polycyclic aromatic compounds as anticancer agents: Synthesis and biological evaluation of dibenzofluorene derivatives

Highly regioselective electrophilic substitution of dibenzofluorene was achieved and the nitro derivative was transformed to a variety of new anticancer agents. Copyright (C) 2000 Elsevier Science Ltd.

Polycyclic aromatic compounds as anticancer agents: Synthesis and biological evaluation of some chrysene derivatives

Synthesis and biological evaluation of new chrysene derivatives aimed at the development of anticancer agents were carried out.